abstract |
The present disclosure relates to the use of an A3AR agonist, such as IB-MECA, for the treatment or prevention of uveitis in a subject, as well as to methods for such treatment and pharmaceutical compositions comprising an amount of IB-MECA effective to treat uveitis. |